Many players in BCL-2 family affairs

Trends in Biochemical Sciences

Volumn 39, Issue 3, 2014, Pages 101-111

  Moldoveanu, Tudor ^a   Follis, Ariele Viacava ^a   Kriwacki, Richard W ^a   Green, Douglas R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

B cell lymphoma 2 (BCL 2) family proteins; Mitochondrial apoptosis; Mitochondrial outer membrane permeabilization (MOMP)

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; OUTER MEMBRANE PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PROTEIN P53;

ALLOSTERISM; APOPTOSIS; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; MEMBRANE PERMEABILITY; MOLECULAR MECHANICS; NONHUMAN; OLIGOMERIZATION; PLASTICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

MAMMALIA;

B CELL LYMPHOMA-2 (BCL-2) FAMILY PROTEINS; MITOCHONDRIAL APOPTOSIS; MITOCHONDRIAL OUTER-MEMBRANE PERMEABILIZATION (MOMP);

ANIMALS; APOPTOSIS; HUMANS; MITOCHONDRIAL MEMBRANES; PERMEABILITY; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84896697241     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2013.12.006     Document Type: Review

References (105)

1. Hotchkiss R.S., et al. Cell death. N. Engl. J. Med. 2009, 361:1570-1583.
2. Green D.R. Apoptotic pathways: ten minutes to dead. Cell 2005, 121:671-674.
3. Jiang X., Wang X. Cytochrome c-mediated apoptosis. Annu. Rev. Biochem. 2004, 73:87-106.
4. Enari M., et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 391:43-50.
5. Suzuki J., et al. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science 2013, 341:403-406.
6. Chipuk J.E., et al. The BCL-2 family reunion. Mol. Cell 2010, 37:299-310.
7. Gross A., et al. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999, 13:1899-1911.
8. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
9. Lessene G., et al. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 2008, 7:989-1000.
10. Chipuk J.E., Green D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol. 2008, 18:157-164.
11. Chou J.J., et al. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 1999, 96:615-624.
12. Hinds M.G., et al. Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ. 2007, 14:128-136.
13. Llambi F., et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell 2011, 44:517-531.
14. Sattler M., et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275:983-986.
15. Moldoveanu T., et al. BID-induced structural changes in BAK promote apoptosis. Nat. Struct. Mol. Biol. 2013, 20:589-597.
16. Czabotar P.E., et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 2013, 152:519-531.
17. Walensky L.D. Direct BAKtivation. Nat. Struct. Mol. Biol. 2013, 20:536-538.
18. Gavathiotis E., et al. BAX activation is initiated at a novel interaction site. Nature 2008, 455:1076-1081.
19. Edlich F., et al. Bcl-xL retrotranslocates Bax from the mitochondria into the cytosol. Cell 2011, 145:104-116.
20. Dai H., et al. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J. Cell Biol. 2011, 194:39-48.
21. Leshchiner E.S., et al. Direct activation of full-length proapoptotic BAK. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E986-E995.
22. Moldoveanu T., et al. The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol. Cell 2006, 24:677-688.
23. Kim H., et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell 2009, 36:487-499.
24. Wei M.C., et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000, 14:2060-2071.
25. Dai H., et al. Evaluation of the BH3-only protein Puma as a direct Bak activator. J. Biol. Chem. 2014, 289:89-99.
26. Du H., et al. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J. Biol. Chem. 2011, 286:491-501.
27. Ren D., et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 2010, 330:1390-1393.
28. Kim H., et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 2006, 8:1348-1358.
29. Shamas-Din A., et al. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol. 2013, 5:a008714.
30. Dewson G., et al. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Mol. Cell 2008, 30:369-380.
31. Griffiths G.J., et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J. Cell Biol. 1999, 144:903-914.
32. Hsu Y.T., Youle R.J. Nonionic detergents induce dimerization among members of the Bcl-2 family. J. Biol. Chem. 1997, 272:13829-13834.
33. Bleicken S., et al. Molecular details of Bax activation, oligomerization, and membrane insertion. J. Biol. Chem. 2010, 285:6636-6647.
34. Dewson G., et al. Bax dimerizes via a symmetric BH3:groove interface during apoptosis. Cell Death Differ. 2012, 19:661-670.
35. Oh K.J., et al. Conformational changes in BAK, a pore-forming proapoptotic Bcl-2 family member, upon membrane insertion and direct evidence for the existence of BH3-BH3 contact interface in BAK homo-oligomers. J. Biol. Chem. 2010, 285:28924-28937.
36. George N.M., et al. A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev. 2007, 21:1937-1948.
37. Aluvila S., et al. Organization of the mitochondrial apoptotic BAK pore: oligomerization of the BAK homodimers. J. Biol. Chem. 2013, 10.1074/jbc.M113.526806.
38. Dewson G., et al. Bak activation for apoptosis involves oligomerization of dimers via their alpha6 helices. Mol. Cell 2009, 36:696-703.
39. Ma S., et al. Assembly of the Bak apoptotic pore: a critical role for the Bak alpha6 helix in the multimerization of homodimers during apoptosis. J. Biol. Chem. 2013, 288:26027-26038.
40. Annis M.G., et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J. 2005, 24:2096-2103.
41. Liu Q., Gehring K. Heterodimerization of BAK and MCL-1 activated by detergent micelles. J. Biol. Chem. 2010, 285:41202-41210.
42. Zhou L., Chang D.C. Dynamics and structure of the Bax-Bak complex responsible for releasing mitochondrial proteins during apoptosis. J. Cell Sci. 2008, 121:2186-2196.
43. Chipuk J.E., et al. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005, 309:1732-1735.
44. Follis A.V., et al. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat. Chem. Biol. 2013, 9:163-168.
45. Chipuk J.E., et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
46. Leu J.I., et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004, 6:443-450.
47. Petros A.M., et al. Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett. 2004, 559:171-174.
48. Day C.L., et al. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J. Mol. Biol. 2008, 380:958-971.
49. Petros A.M., et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 2000, 9:2528-2534.
50. Ku B., et al. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 2011, 21:627-641.
51. Liu Q., et al. Apoptotic regulation by MCL-1 through heterodimerization. J. Biol. Chem. 2010, 285:19615-19624.
52. Cartron P.F., et al. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol. Cell 2004, 16:807-818.
53. Gallenne T., et al. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J. Cell Biol. 2009, 185:279-290.
54. Suzuki M., et al. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000, 103:645-654.
55. Gavathiotis E., et al. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol. Cell 2010, 40:481-492.
56. Korsmeyer S.J., et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000, 7:1166-1173.
57. Edwards A.L., et al. Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. Chem. Biol. 2013, 20:888-902.
58. LaBelle J.L., et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J. Clin. Invest. 2012, 122:2018-2031.
59. Sot B., et al. Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL. J. Biol. Chem. 2007, 282:29193-29200.
60. Pietsch E.C., et al. Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J. Biol. Chem. 2008, 283:21294-21304.
61. Chipuk J.E., et al. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003, 4:371-381.
62. Schuler M., Green D.R. Transcription, apoptosis and p53: catch-22. Trends Genet. 2005, 21:182-187.
63. Green D.R., Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-1130.
64. Hagn F., et al. Bcl-xL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J. Biol. Chem. 2010, 285:3439-3450.
65. Petros A.M., et al. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 2004, 1644:83-94.
66. Tomita Y., et al. WT p53, but not tumor-derived mutants, bind to Bcl-2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem. 2006, 281:8600-8606.
67. Bharatham N., et al. Molecular basis of Bcl-X(L)-p53 interaction: insights from molecular dynamics simulations. PLoS ONE 2012, 6:e26014.
68. Xu H., et al. The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-X(L)-binding motif. Biochemistry 2009, 48:12159-12168.
69. Ha J.H., et al. Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways. J. Biol. Chem. 2013, 288:7387-7398.
70. Arnoult D., et al. Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:7988-7993.
71. Handke W., et al. Live or let die: manipulation of cellular suicide programs by murine cytomegalovirus. Med. Microbiol. Immunol. 2012, 201:475-486.
72. Cam M., et al. Cytomegaloviruses inhibit Bak- and Bax-mediated apoptosis with two separate viral proteins. Cell Death Differ. 2010, 17:655-665.
73. Handke W., et al. Viral inhibition of BAK promotes murine cytomegalovirus dissemination to salivary glands. J. Virol. 2013, 87:3592-3596.
74. Kvansakul M., Hinds M.G. Structural biology of the Bcl-2 family and its mimicry by viral proteins. Cell Death Dis. 2013, 4:e909.
75. Ma J., et al. Structural mechanism of Bax inhibition by cytomegalovirus protein vMIA. Proc. Natl. Acad. Sci. U.S.A. 2013, 109:20901-20906.
76. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5:876-885.
77. Lee E.F., et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 2007, 14:1711-1713.
78. Oltersdorf T., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
79. van Delft M.F., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
80. Shuker S.B., et al. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
81. Ackler S., et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol. Cancer Ther. 2008, 7:3265-3274.
82. Shoemaker A.R., et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res. 2008, 14:3268-3277.
83. Tse C., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
84. Balakrishnan K., Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest. New Drugs 2013, 31:1384-1394.
85. Ackler S., et al. Navitoclax (ABT-263) and bendamustine +/- rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br. J. Pharmacol. 2012, 167:881-891.
86. Chen J., et al. The Bcl-2/Bcl-xL/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol. Cancer Ther. 2011, 10:2340-2349.
87. Souers A.J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19:202-208.
88. Vogler M., et al. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br. J. Haematol. 2013, 163:139-142.
89. Touzeau C., et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2014, 28:210-212.
90. Vaillant F., et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013, 24:120-129.
91. Lessene G., et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 2013, 9:390-397.
92. Petros A.M., et al. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg. Med. Chem. Lett. 2010, 20:6587-6591.
93. Beroukhim R., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
94. Ng K.P., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 2012, 18:521-528.
95. Sarosiek K.A., et al. Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol. 2013, 51:751-765.
96. Galluzzi L., et al. Targeting post-mitochondrial effectors of apoptosis for neuroprotection. Biochim. Biophys. Acta 2009, 1787:402-413.
97. Gavathiotis E., et al. Direct and selective small-molecule activation of proapoptotic BAX. Nat. Chem. Biol. 2012, 8:639-645.
98. Higueruelo A.P., et al. Protein-protein interactions as druggable targets: recent technological advances. Curr. Opin. Pharmacol. 2013, 13:791-796.
99. Kale J., et al. Shedding light on apoptosis at subcellular membranes. Cell 2012, 151:1179-1184.
100. Varadarajan S., et al. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ. 2013, 20:1475-1484.
101. Wang X., et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013, 27:1351-1364.
102. Friberg A., et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J. Med. Chem. 2013, 56:15-30.
103. Happo L., et al. BH3-only proteins in apoptosis at a glance. J. Cell Sci. 2012, 125:1081-1087.
104. Shamas-Din A., et al. BH3-only proteins: orchestrators of apoptosis. Biochim. Biophys. Acta 2011, 1813:508-520.
105. Muchmore S.W., et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996, 381:335-341.